Tazemetostat

1. Tazemetostat decreases senescence-associated secretory phenotype (SASP) in humans.

   “Treatment of tendon biopsies with EPZ-6438 reduced secretion of a panel of SASP factors, including interleukin-6 (IL6), IL8, matrix metalloproteinase-3 (MMP3) or GRO1”

   Human trialex vivo tendon biopsiestendon

   Occurrence of cellular senescence in chronic human shoulder tendinopathies and its attenuation ex vivo by inhibition of Enhancer of Zeste 2

   Bone & joint research·Feb 25, 2025

More on Senescence-associated secretory phenotype (SASP)

1. Tazemetostat increases food intake in mice.

   “mitigated the reduced food intake and impaired body weight gain characteristic of this strain”

   Animalsin klotho mice160 mg/kg twice a day3 weeks

   Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach

   Cellular and molecular gastroenterology and hepatology·Jul 3, 2024

1. Tazemetostat improves gastric slow wave activity in mice.

   “EPZ6438 also improved gastric slow wave activity and mitigated the reduced food intake and impaired body weight gain characteristic of this strain.”

   Animalsin klotho mice160 mg/kg twice a day3 weeks

   Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach

   Cellular and molecular gastroenterology and hepatology·Jul 3, 2024

1. Tazemetostat decreases ICC decline in mice.

   “In klotho mice, EPZ6438 treatment mitigated the decline in the ICC growth factor KIT ligand/stem cell factor and gastric ICC.”

   Animalsin klotho mice160 mg/kg twice a day3 weeks

   Inhibition of EZH2 Reduces Aging-Related Decline in Interstitial Cells of Cajal of the Mouse Stomach

   Cellular and molecular gastroenterology and hepatology·Jul 3, 2024